U.S. stock index futures pointed to a slightly higher open on Tuesday, as investors prepared themselves for a deluge of earnings and data.
Third-quarter sales at the world's biggest maker of cancer drugs rose to $12.61 billion.
Stocks closed lower as investors digested a number of corporate results, key economic data and remarks from a key Fed official.
The "Fast Money Halftime Report" traders, Kevin O'Leary, O'Shares Chairman and "Shark Tank" star, and Ian Winer, Wedbush, share their takes on the health care sector, including Merck after Bank of America's call to upgrade the stock to buy.
Stocks closed sharply lower as new fears about the U.S. election weighed on the broader market, while crude prices fell.
Stocks closed higher, led by energy, following the second presidential debate while investors digested a rise in oil prices.
CNBC's Meg Tirrell reports the latest in biotech, including what is next for Mylan following the company's EpiPen settlement with the U.S. Department of Justice.
CNBC's Meg Tirrell reports on the moves in cancer drugmakers following the European Cancer Congress in Copenhagen. The "FMHR" traders weigh in.
Some of the names on the move ahead of the open.
Bristol-Myers Squibb's approach to treating lung cancer will have a chance to redeem itself when new data comes out on Sunday.
CNBC's Meg Tirrell reports on why billions are at stake for Bristol-Myers and Merck. The “Fast Money” traders weigh in.
Half of Alnylam Pharmaceuticals' $6 billion market value evaporated Thursday after patient deaths ended a drug trial.
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in.
The dogs of the dow surge. So what's next? With CNBC's Melissa Lee and the Options Action traders.
RSV — or respiratory syncytial virus — has been a problem that's thwarted medicine for more than half a century.
Aside from the financial crisis, health care hasn't lagged the broader market this badly since Bill Clinton was president.
Stocks traded mixed as investors digested remarks made by Federal Reserve Chair Janet Yellen and Vice Chairman Stanley Fischer.
Mylan has raised the price of EpiPens more than 400 percent in recent years. The medicine inside costs $1.
CNBC Pro used Symmetric.io, a tracking research firm, to find the top health care stocks owned by hedge funds with the best health-care stock-picking records.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.